Esophagogastric Junction Adenocarcinoma Clinical Trials

5 recruiting

Esophagogastric Junction Adenocarcinoma Trials at a Glance

7 actively recruiting trials for esophagogastric junction adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Frankfurt, and Hamburg. Lead sponsors running esophagogastric junction adenocarcinoma studies include Ruijin Hospital, Biotech Pharmaceutical Co., Ltd., and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse esophagogastric junction adenocarcinoma trials by phase

Treatments under study

About Esophagogastric Junction Adenocarcinoma Clinical Trials

Looking for clinical trials for Esophagogastric Junction Adenocarcinoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophagogastric Junction Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophagogastric Junction Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Peritoneal Metastases From Gastric CancerGastric Cancer Stage IVGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital74 enrolled1 locationNCT07556640
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Gastric AdenocarcinomaEsophagogastric Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences70 enrolled1 locationNCT06761846
Recruiting
Phase 2

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric CancerEsophagogastric Junction Adenocarcinoma
Zekuan Xu30 enrolled1 locationNCT06461910
Recruiting
Phase 1

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Neoadjuvant TherapyEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest18 enrolled4 locationsNCT07059299
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Esophagogastric Junction Adenocarcinoma
Sun Yat-sen University37 enrolled1 locationNCT05170503
Recruiting
Phase 3

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

Gastric or Esophagogastric Junction Adenocarcinoma
Biotech Pharmaceutical Co., Ltd.354 enrolled1 locationNCT05978050
Recruiting
Phase 2

Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study

Esophagogastric Junction Adenocarcinoma
Ruijin Hospital26 enrolled1 locationNCT06482788